Leukemia Clinical Trials in Boston

Showing 341-360 of 1,445 trials

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

NCT03042689

This research study is studying a drug as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative neoplasms) The intervention involved in this study is: -Regorafenib (Stivarga)

Acute Myeloid Leukemia

Massachusetts General Hospital16 participantsStarted Apr 2017

Boston, Massachusetts, United States

TERMINATEDPhase 2< 1 mile

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

NCT03425331

This research study is studying two immunotherapy drugs as a possible treatment for advanced non-small cell lung cancer (NSCLC). The drugs involved in this study are: * Ipilimumab * Nivolumab

Non-small Cell Lung Cancer

Dana-Farber Cancer Institute5 participantsStarted Apr 2018

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

Active Not RecruitingPhase 1< 1 mile

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

NCT02787369

This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Recurrent Chronic Lymphoid Leukemia

Dana-Farber Cancer Institute3 participantsStarted May 2016

Boston, Massachusetts, United States

Active Not RecruitingPhase 1< 1 mile

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal Cell+9 more

Novartis Pharmaceuticals126 participantsStarted Oct 2022

Boston, Massachusetts, United States • Boston, Massachusetts, United States • New York, New York, United States +16 more locations

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Leukemia Trials in Other Cities

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Other Conditions in Boston